Kangyuan Pharmaceutical released its 2026 half-year report, showing first-half net profit attributable to the parent of 147 million yuan, up 3.4% year on year. Operating revenue was 1.66 billion yuan, up 1.2% year on year. Net profit attributable to the parent after deducting non-recurring items was 129 million yuan, up 7.5% year on year. Net operating cash flow was 82.1 million yuan, down 43.1% year on year. Earnings per share were 0.2599 yuan. In the second quarter, operating revenue was 830 million yuan, up 8.7% year on year. Net profit attributable to the parent was 67.88 million yuan, up 15.1% year on year. Net profit attributable to the parent after deducting non-recurring items was 56.92 million yuan, up 49.8% year on year. As of the end of the second quarter, total assets were 6.972 billion yuan, up 1.6% from the end of the previous year. Net assets attributable to the parent were 4.966 billion yuan, up 3.1% from the end of the previous year. The company said that during the reporting period it continued to advance the construction of a professional marketing system, with product lines in respiratory and infectious diseases, cardiovascular and cerebrovascular diseases, and gynecology performing well. The advantages of exclusive varieties continued to be released, and the company promoted digital transformation and strengthened cooperation with pharmaceutical commercial companies, with overall operations remaining stable and improving.
Jiangsu Kanion Pharmaceutical Co LtdFirst-half net profit up 3.4% and Q2 net profit up 15.1%, with revenue growth and stable operations.
